# An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

> **NCT00201357** · PHASE2 · COMPLETED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 30 (actual)

## Conditions studied

- Hormone-refractory Prostate Cancer

## Interventions

- **DRUG:** Thalidomide (THADO)

## Key facts

- **NCT ID:** NCT00201357
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00201357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00201357, "An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00201357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*